MedTrace Logo

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

NCT05333159 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1424

Last updated 2022-04-18

No results posted yet for this study

Summary

The study is to compare the effects of SGLT-2 inhibitors and other oral hypoglycemic agents in patients with coronary heart disease and diabetes mellitus undergoing percutaneous coronary intervention.

Conditions

Interventions

DRUG

SGLT2 inhibitor

dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • xiaofan Wu, MD · Beijing Anzhen Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-12-30
Completion
2024-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05333159 on ClinicalTrials.gov